Moderna Stock News

Vaccines against the herpes virus, and chickenpox, are being developed by US biotech company Moderna US biotech company Moderna disclosed this Friday, February 18, that it is developing vaccines against the herpes simplex virus (HSV), and also to combat varicella-zoster virus (VZV), which causes chickenpox. Another treatment the company is working on is based on [] The post Moderna is developing vaccines against the herpes virus, and chickenpox appeared first on Euro Weekly News Spain .

This weekend''s Barron''s cover story says the Fed is facing a lot of pressure with growing concerns about a recession, although some believe the U.S. central bank can combat inflation while maintaining economic growth. Other featured articles discuss why the performance of a food delivery stock shows at-home eating will be a lasting habit, and why the director of a top automaker is buying the company stock as is drops by double digits. Also, General Electric signals that supply-chain problems aren''t going away, and a pharmaceutical company uses COVID-19 vaccine revenue to expand its pipeline of products. " The Fed Doesnt Have a Playbook to Tame Inflation While Avoiding a Recession ," by Lisa Beilfuss, says the stakes are high for the U.S. central bank, and for every professional prognosticator who is sure a recession is inevitable, theres another one predicting that the Fed can combat inflation without reversing economic growth. In "

Wall Street Journal says regulator could authorize fourth shots of Pfizer and Moderna vaccines by the fall US health regulators are looking at authorizing a potential fourth dose of a Covid-19 vaccine in the fall, the Wall Street Journal reported on Saturday, citing sources familiar with the matter. The Food and Drug Administration (FDA) has been reviewing data to authorize a second booster dose of vaccines from Pfizer and BioNTech and Moderna, the report added . Continue reading

The Food and Drug Administration has been reviewing data to authorise a second booster dose of the messenger RNA vaccines from Pfizer Inc and partner BioNTech SE and vaccines from Moderna Inc

The agency has begun reviewing data that could lead to clearing a second booster dose of the Pfizer and Moderna vaccines in the fall, if they are found to work safely.

It has to do with the next stage of the health crisis.

Moderna has applied for patents in South Africa for its Covid-19 vaccine, prompting fears the company could eventually seek to prevent a new African vaccine manufacturing hub from making its own version of the mRNA shot.

The S&P 500 is off almost 9% for the year-to-date, but the biggest decliners in the main benchmark of U.S. equity performance are faring far, far worse. From small, somewhat obscure members of the index to the planet''s best-known and biggest stocks, the S&P 500''s most beaten-down names do have at least a few commonalities. SEE MORE The 22 Best Stocks to Buy for 2022 For one thing, they''re all well into bear-market territory , down at least 27% on a price basis for the year-to-date. Some of these stocks are suffering the flip side after having been among last year''s biggest winners. Any number of stocks that rallied as pandemic or COVID-19 recovery plays in 2021 have seen much of their gains evaporate this year. Additionally, inflation, interest-rate anxiety and geopolitical tension have been particularly hard on pricey growth stocks in 2022. The tense background and shift in sentiment has made for an unusually punishing earnings season. Woe to any company that misses Wall Street estimates – or worse – issues downbeat guidance.

CEO Stéphane Bancel said the company is confident enough, and has enough capital, for a big study that would bring the vaccine to market faster.

Moderna and Pfizer''s vaccine were seeing India as a big market.

Talks did not materialise, says Niti Aayog''s VK Paul on Pfizer and Moderna

Moderna Inc (NASDAQ: MRNA ) said it is developing three new vaccines based on the same technology used for its COVID-19 shot, including one for viral infection shingles. The success of COVID-19 vaccines based on messenger RNA (mRNA) technology from Moderna and rival Pfizer Inc (NYSE: PFE ) / BioNTech SE (NASDAQ: BNTX ) has prompted efforts to use the novel … Full story available on Benzinga.com

Moderna (MRNA) said it is expanding its mRNA pipeline with three new development programs.The programs are: herpes simplex virus ((HSV)) vaccine candidate mRNA-1608; varicella-zoster…

Shares of Moderna Inc. gained 0.1% on Friday after the company said it is now developing mRNA vaccines for herpes simplex virus, varicella-zoster virus (against shingles), and certain types of cancer, starting with advanced or metastatic melanoma and non-small cell lung carcinoma. The company''s stock is down 13.7% over the past year, while the broader S&P 500 is 11.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Canada approved, on Thursday, the Novavax COVID-19 vaccine for people aged 18 and over. The announcement makes “Novavax” the fifth COVID-19 vaccine authorized in the country after AstraZeneca, Moderna, Pfizer and Johnson & Johnson. In a news release, Health Canada said the vaccine is 90% effective at preventing symptomatic COVID-19 and 100% effective at preventing […]